Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 391

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 391
---
001 project (see above).

As required by IFRS 5, the other intangible assets of Opella were measured in accordance with IAS 36 immediately before their

reclassification as assets held for sale; this assessment did not result in any impairment of their carrying amount being recognized.

Property, plant and equipment

Impairment losses taken against property, plant and equipment are disclosed in Note D.3.

Risks and opportunities related to climate change

Sanofi has identified specific plausible scenarios to assess climate risks and opportunities liable to impact its activities in the

medium and longer term.

These include:

• an Aggressive Mitigation scenario, based on global collaboration to start reducing emissions immediately to meet Paris

Agreement goals (limit temperature increase to 1.5°C above pre-industrial levels), generating risks related to transitioning to a

lower carbon economy and entailing extensive policy, legal, technology, and market changes to address mitigation and

adaptation requirements;

• a No Climate Action scenario (leading to global warming of 4°C above pre-industrial levels by 2100), with event-driven physical

risks resulting from climate change or longer term shifts in climate patterns leading to potential financial implications such as

direct damage to assets and indirect impacts from supply chain disruption; changes in water availability, and in the sourcing or

quality of resources; food security; and extreme temperature changes affecting premises, operations, supply chain, transport

needs, and employee safety; and

• a Most Likely scenario, encompassing fragmented regional efforts to start reducing emissions but not at a sufficient level to

meet Paris Agreement g oals (emissions continue to increase but at a slowed rate, leading to a 2.8°C temperature increase).

The importance and likelihood of such risks have been assessed and have not led Sanofi to identify any material impact that could

generate a risk of impairment of the assets of Sanofi’s CGUs.

| SANOFIFORM 20-F2024 | F-45 |

| NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS |

D.6. Investments accounted for using the equity method

Investments accounted for using the equity method comprise associates and joint ventures (see Note B.1.), and are set forth

below.

| (€ million)                       | % interest | 2024 | 2023 | 2022 |
| EUROAPI(a)                        |       29.6 |   82 |  162 |  392 |
| Infraserv GmbH & Co. Hö